FTC opens in­ves­ti­ga­tion in­to largest PBM­s' an­ti­com­pet­i­tive prac­tices

The Fed­er­al Trade Com­mis­sion is turn­ing up the heat on the drug in­dus­try’s mid­dle­men, launch­ing an in­ves­ti­ga­tion in­to phar­ma­cy ben­e­fit man­ag­er prac­tices and the ef­fect on drug prices. The move comes just a few months af­ter a dif­fer­ent study pro­pos­al failed to gain enough sup­port among the FTC com­mis­sion­ers in a 2-2 tie vote.

Now with a re­vamped study and new­ly ap­point­ed Pres­i­dent Biden pick Al­varo Bedoya on board, the com­mis­sion vot­ed unan­i­mous­ly 5-0 to dig in­to PBM prac­tices.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER